Immunotherapy with dendritic cells in a humanised mouse model of rheumatoid arthritis

在类风湿性关节炎人源化小鼠模型中使用树突状细胞进行免疫治疗

• 批准号: G0601211/1
• 负责人: Catharien Hilkens
• 金额: $ 49.13万
• 依托单位: Newcastle University
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0601211%2F1
• 关键词: Immunotherapy; dendritic; cells; humanised; mouse

We aim to develop a new therapy for rheumatoid arthritis (RA) using a type of immune cell called a dendritic cell (DC). RA is a painful disease that leads to stiffness and deformity of joints in hands, feet and limbs. Almost 400,000 people in the UK suffer from RA. No cure for this disease is available yet.RA is caused by a patient’s own immune system: white blood cells mistakenly attack joints and cause destruction of cartilage and bone. We have made a special type of DC with the ability to prevent white blood cells attacking the joint (i.e. make the blood cells ‘tolerant’) and hope this can be used to treat RA. This type of DC is called tolerogenic DC (tolDC).Our work addresses important questions that must be answered before we can test tolDC treatment in humans. For instance, we need to know how many tolDC will be required to inhibit arthritis; where they will have to be injected (e.g. in the blood, in the joint); how long they will survive in the body; and how they make white blood cells tolerant. We will address these questions using mice which develop a disease similar to RA.If successful, our work will bring a new and hopefully beneficial treatment for RA closer to clinical use.

我们的目标是使用一种称为树突状细胞 (DC) 的免疫细胞开发一种治疗类风湿性关节炎 (RA) 的新疗法。类风湿性关节炎是一种痛苦的疾病，会导致手、足和四肢关节僵硬和畸形。英国有近 400,000 人患有 RA。这种疾病目前尚无治愈方法。 RA 是由患者自身的免疫系统引起的：白细胞错误地攻击关节并导致软骨和骨骼破坏。我们制造了一种特殊类型的 DC，能够防止白细胞攻击关节（即使血细胞“耐受”），并希望它可以用于治疗 RA。这种类型的 DC 称为耐受性 DC (tolDC)。我们的工作解决了在人类测试 tolDC 治疗之前必须回答的重要问题。例如，我们需要知道需要多少 tolDC 才能抑制关节炎；必须注射的地方（例如血液中、关节中）；它们会在体内存活多久；以及它们如何使白细胞具有耐受性。我们将使用患有类似 RA 疾病的小鼠来解决这些问题。如果成功，我们的工作将为 RA 带来一种新的、有望有益的治疗方法，更接近临床应用。